Telomir Pharmaceuticals, Inc. TELO 深 滬
已收盤 05-22 16:00:00 美东时间
1.29
-0.010
-0.77%
華盛通- 最 高1.30
- 今 開1.30
- 成交量 5.39万股
- 最 低 1.24
- 昨 收 1.30
- 總市值 8871.97万
- 52周最高 3.10
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 1.05
- 委 比 -30.38%
- 總股本 6877.50万
- 歷史最高 20.72
- 量 比 0.56
- 振 幅 4.62%
- 歷史最低 1.05
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Telomir Pharma Announces Peer-Reviewed Publication Of Preclinical Data Showing Telomir-Zn Produced Dose-Dependent Survival Improvement Across Multiple Endpoints In Wilson's Disease Model
Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease
05-20 20:04
EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study
Telomir wins FDA IND clearance for Telomir-Zn in TNBC, enabling a Phase 1/2 study targeting epigenetic cancer pathways.
04-30 19:46
Telomir Pharmaceuticals Submits Investigational New Drug Application To FDA To Treat Advanced And Metastatic Triple-Negative Breast Cancer
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today
03-31 20:23
Telomir Pharmaceuticals Announces New Data Supporting Telomir-Zn's Mechanism In Cancer And Aging, Plans Submission For Investigational New Drug Application In Q1 2026
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms.
02-05 21:09
Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC
Telomir Pharmaceuticals, Inc. ( ($TELO) ) just unveiled an update. Telomir Phar...
01-05 21:39
Telomir Pharmaceuticals Results From Trial In Zebrafish Tumor Xenograft Animal Models Of Triple-Negative Breast Cancer Shows Reductions In Primary Tumor Growth, Spread Of Cancer Cells
Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of diseases, today announced
01-05 21:07
Telomir Pharma Announces Results From Comprehensive Series Of IND-Enabling GLP Toxicology And Safety Pharmacology Studies For Telomir-1
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration.MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals,
2025-12-18 20:32
Telomir Pharmaceuticals Announces Telomir-1 Shown To Kill Aggressive Human Leukemia Cells
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells The findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative
2025-11-21 05:05
Telomir Pharmaceuticals Q3 EPS $(0.03) Beats $(0.07) Estimate
Telomir Pharmaceuticals (NASDAQ:TELO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 85 percent increase over losses of $(0.20) per share
2025-11-11 07:00
Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). ...
2025-10-23 04:40
